Astaxanthin composition and preparation method thereof

By constructing astaxanthin-embedded microparticle compositions and using materials such as resistant dextrin to build a stable shell, the demulsification layering problem caused by glycosaminoglycan is solved, and the stability and application effect of astaxanthin at high temperatures is ensured. .

CN119074705AActive Publication Date: 2024-12-06BY HEALTH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411176810.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-06
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

When the existing astaxanthin embedding system is used in the food and cosmetics fields, demulsification and stratification problems caused by glycosaminoglycans are prone to occur, especially during high-temperature sterilization, which leads to astaxanthin degradation and content. The decrease limits its combination application with glycosaminoglycan components.

Method used

Astaxanthin-embedded microparticle composition, including astaxanthin as the inner core and glycosaminoglycan as the shell, resistant dextrin, maltodextrin, etc. as the skeleton component, gum arabic, etc. as the thickener, medium chain glycerol Triacid acids, etc. are used as emulsifiers to build a stable embedded structure and process them under autoclave to ensure that the composition remains stable at high temperature.

Benefits of technology

The structural stability of astaxanthin-embedded particles under high temperature conditions is achieved, the demulsification and degradation are avoided, and the uniform dispersion and efficient application in food and cosmetics is ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074705A_ABST
    Figure CN119074705A_ABST
Patent Text Reader

Abstract

The invention relates to a composition. The composition comprises astaxanthin embedded particles and glycosaminoglycans. The structure of the astaxanthin embedded particle comprises an inner core and a shell, the inner core comprises astaxanthin, and the shell comprises a skeleton component, a thickening agent and an emulsifier. According to the astaxanthin embedded microparticles, the dextrin component is adopted as a skeleton component, the thickener and the emulsifier are matched to construct an astaxanthin embedded shell, and the prepared astaxanthin embedded microparticles are stable in structure, are compounded with glycosaminoglycan components, are uniformly dispersed in water without demulsification and layering phenomena, and are still kept stable under a high-temperature condition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of embedded preparations, and in particular relates to an astaxanthin embedded microparticle composition and a preparation method thereof. Background Art

[0002] Astaxanthin, chemical name 3,3′-dihydroxy-4,4′-diketo-β-carotene, is a keto-carotenoid. Astaxanthin is a red solid powder with a very good coloring effect and can be used as a natural colorant. In addition, astaxanthin has extremely strong antioxidant properties, which is 10 times that of β-carotene and 500 times that of vitamin E. It is called "super vitamin E". Due to its excellent antioxidant function and coloring effect, it is now widely used in functional foods, cosmetics and other fields.

[0003] Astaxanthin is an oily substance with very good fat solubility, but it is insoluble in water. Since a large number of foods and cosmetics are water-soluble systems, the solubility of astaxanthin greatly limits its industrial application. A common solution is to improve its hydrophilicity through encapsulation technology, which can also improve the tolerance of astaxanthin preparations to temperature, light and pH.

[0004] CN108013441A discloses an astaxanthin embedding complex and a preparation method thereof, which uses sodium carboxymethylcellulose CMC-Na and microcrystalline cellulose MCC to embed astaxanthin, thereby improving the hydrophilicity of astaxanthin, and the embedded astaxanthin is applied to the development of yogurt products. CN111358762A discloses an astaxanthin microcapsule, which uses β-cyclodextrin, oligomaltose and modified starch to embed astaxanthin, thereby greatly improving the water solubility of astaxanthin and increasing its bioavailability.

[0005] Although conventional embedding can solve the problem of astaxanthin solubility, the applicant has found that many existing astaxanthin embedding systems will cause demulsification and stratification when used in the fields of food and cosmetics when the product contains glycosaminoglycans. Moreover, when the corresponding products are sterilized at high temperatures, the demulsification and stratification phenomenon will be aggravated, further leading to astaxanthin degradation and reduced astaxanthin content, affecting the efficacy of astaxanthin in the product. This greatly limits the compound application of astaxanthin and glycosaminoglycans. Summary of the invention

[0006] In view of the problem that glycosaminoglycan components of the existing astaxanthin embedding system are easy to demulsify and stratify, the present invention provides an astaxanthin-embedded microparticle composition and a preparation method thereof.

[0007] In a first aspect, the present invention provides a composition comprising astaxanthin-embedded microparticles and glycosaminoglycan; the structure of the astaxanthin-embedded microparticles comprises an inner core and an outer shell; the inner core component comprises astaxanthin, and the outer shell component comprises a skeleton component, a thickener and an emulsifier.

[0008] In certain embodiments, the matrix component is selected from one or more of resistant dextrin, maltodextrin, and β-cyclodextrin.

[0009] In certain embodiments, the thickener is selected from one or more of gum arabic, xanthan gum, pectin, and guar gum.

[0010] In certain embodiments, the emulsifier is selected from medium chain triglycerides, and / or glyceryl succinate.

[0011] In certain embodiments, the astaxanthin is astaxanthin oil.

[0012] In certain embodiments, the composition is uniformly dispersed in water and is in the form of an emulsion.

[0013] In certain embodiments, the mass ratio of the inner core to the outer shell is 1:10-100.

[0014] In certain embodiments, the mass ratio of the inner core to the outer shell is 1:20-50.

[0015] In certain embodiments, the mass ratio of the skeleton component, the thickener, and the emulsifier is 1-2:2-6:1-2.

[0016] In certain embodiments, the mass ratio of the skeleton component, the thickener, and the emulsifier is 1:3:1.

[0017] In certain embodiments, the glycosaminoglycan is selected from one or more of hyaluronic acid, chondroitin sulfate, dermatan sulfate, and keratan sulfate.

[0018] In certain embodiments, the composition further comprises collagen.

[0019] In certain embodiments, the glycosaminoglycan molecules are polymerized to collagen molecules.

[0020] In certain embodiments, the collagen is glycosaminoglycan-rich collagen.

[0021] In certain embodiments, the mass ratio of astaxanthin to glycosaminoglycan is 1:2-7.

[0022] In certain embodiments, the composition further comprises a pH adjuster.

[0023] In certain embodiments, the pH adjuster is selected from one or more of citric acid, malic acid, and tartaric acid.

[0024] In a second aspect, the present invention provides a method for preparing a composition, the preparation method comprising the following steps:

[0025] (1) adding the inner core and outer shell components described in the first aspect to an appropriate amount of water and stirring until the components are fully dissolved to prepare a solution for use;

[0026] (2) the solution in step (1) is homogenized by a homogenizer to obtain astaxanthin-embedded microparticles, wherein the astaxanthin-embedded microparticles are uniformly dispersed in water in an emulsion state;

[0027] (3) Add glycosaminoglycan to the emulsion and stir until fully dissolved, then sterilize in an autoclave to obtain a composition.

[0028] In certain embodiments, the stirring time in step (1) is 10-40 min.

[0029] In certain embodiments, the homogenization speed in step (2) is 5000-25000 rpm.

[0030] In certain embodiments, the homogenization speed duration in step (2) is 5-15 min.

[0031] In certain embodiments, the stirring time in step (3) is 15-30 min.

[0032] In certain embodiments, the sterilization temperature in step (3) is 105-121° C., and the sterilization time is 15-30 min.

[0033] In a third aspect, the present invention provides the use of the composition described in the previous aspects in the preparation of medicines, health foods, and foods.

[0034] Definition of terms

[0035] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Meanwhile, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0036] As used herein, the term "embedded microparticles" is also known as "microcapsules", which are particles with tiny enclosed spaces, and their sizes can range from micrometers to nanometers. Embedded microparticles are usually composed of a core and an outer shell structure, and the outer shell is also known as a wall material, which can be made of various materials, including natural or synthetic polymer materials. Embedded microparticle technology allows the core material to be protected while allowing specific substances to be released through the wall material for controlled release.

[0037] As used herein, the term "glycosaminoglycan" refers to a repeating disaccharide unit composed of pentosuronic acid or hexosuronic acid connected to N-acetylglucosamine or N-acetylgalactosamine, and some of them have sulfate substitutions at positions 1 / 4 / 6 on the glycosamine; the molecular weight range of glycosaminoglycans is very wide, ranging from several thousand daltons to more than one million daltons. "Glycosaminoglycans" herein include but are not limited to hyaluronic acid, chondroitin sulfate, dermatan sulfate, and keratin sulfate. Glycosaminoglycans can exist alone as a glycosaminoglycan structure, or they can be polymerized onto collagen molecules.

[0038] Advantageous Effects of the Invention

[0039] Compared with the astaxanthin-embedded microparticles in the prior art, the astaxanthin-embedded microparticles of the present invention have at least the following beneficial effects: the present invention adopts dextrin as a skeleton component, and combines a thickener and an emulsifier to construct an astaxanthin-embedded shell, so that the structure of the astaxanthin-embedded microparticles is stable, and when compounded with glycosaminoglycan components, the astaxanthin-embedded microparticles can be evenly dispersed in water without demulsification and stratification. The structure of the astaxanthin-embedded microparticles remains stable under high temperature conditions, further avoiding the degradation of the astaxanthin component. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 is the chromatogram of the astaxanthin standard in Example 6;

[0041] Figure 2 , chromatogram of the test sample of composition 4 in Example 6;

[0042] Figure 3 , chromatogram of the test sample of composition 36 in Example 6. DETAILED DESCRIPTION

[0043] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.

[0044] Unless otherwise indicated, the experiments and procedures described in the examples were performed essentially according to conventional methods well known in the art and described in various references.

[0045] In addition, if the specific conditions are not specified in the examples, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be obtained commercially. It is known to those skilled in the art that the embodiments describe the present invention by way of example and are not intended to limit the scope of the present invention. All public cases and other references mentioned herein are incorporated herein by reference in their entirety.

[0046] Example 1. Preparation of astaxanthin-encapsulated microparticle composition

[0047] In terms of weight percentage, the formula of astaxanthin-embedded microparticles 1-24 in this embodiment is as shown in Table 1-3:

[0048] Table 1 Astaxanthin embedded microparticles formula

[0049]

[0050]

[0051] Table 2 Astaxanthin embedded microparticles formula

[0052]

[0053] Table 3 Astaxanthin embedded microparticles formula

[0054]

[0055] Table 4 Astaxanthin embedded microparticles formula

[0056]

[0057] The preparation process of the astaxanthin embedded microparticles 1-32 of this embodiment:

[0058] (1) mixing the components of the astaxanthin-embedded microparticles and stirring for 10-40 minutes until the components are fully dissolved to prepare a solution for use;

[0059] (2) The solution obtained in step (1) is homogenized by a homogenizer at a speed of 5000-25000 rpm for 5-15 min to obtain astaxanthin-embedded microparticles, wherein the astaxanthin-embedded microparticles are uniformly dispersed in water in an emulsion state.

[0060] Example 2 Preparation of Astaxanthin-Encapsulated Microparticle Composition

[0061] Take the astaxanthin-embedded microparticles 1-32 prepared in Example 1, add 70 parts by weight (based on the weight fraction of astaxanthin oil as 1) of glycosaminoglycan-rich collagen peptide (the preparation method thereof is referred to CN116410302A, the glycosaminoglycan-rich collagen peptide contains 63 parts of collagen peptide and 7 parts of glycosaminoglycan, glycosaminoglycan includes chondroitin sulfate, sodium hyaluronate, dermatan sulfate, etc., wherein the glycosaminoglycan exists in the form of both the structure of glycosaminoglycan alone and polymerization on collagen molecules), then stir with a stirrer for 15-30 minutes until fully dissolved, and place in an autoclave for sterilization (sterilization conditions: temperature 105-121°C, time 15-30 minutes), and obtain a composition 1-32 containing astaxanthin-embedded microparticles.

[0062] Take the astaxanthin particles 1, 12, 27, and 31 prepared in Example 1, add 2 parts of sodium hyaluronate respectively, then stir with a blender for 15-30 minutes until fully dissolved, and place in a high pressure sterilizer for sterilization (sterilization conditions: temperature 105-121°C, time 15-30 minutes) to obtain compositions 33-36 of astaxanthin-encapsulated particles.

[0063] Take the astaxanthin particles 3, 7, 28, and 32 prepared in Example 1, add 5 parts of chondroitin sulfate respectively, and then stir with a blender for 15-30 minutes until fully dissolved, and place in a high pressure sterilizer for sterilization (sterilization conditions: temperature 105-121°C, time 15-30 minutes) to obtain a composition 37-40 of astaxanthin-encapsulated particles.

[0064] Example 3 Sensory testing of astaxanthin-embedded microparticle composition

[0065] 3.1 Test methods

[0066] Take a certain amount of the evenly mixed sample and place it in a 50mL colorless transparent beaker. Observe the color under natural light to check whether there is any foreign matter.

[0067] 3.2 Test results

[0068] Compositions 1-26, 33-34, 37-38 are orange to orange-red liquids, uniform and without stratification, and no oily floating matter; Compositions 27-32, 35-36, 39-40 are stratified, with oily matter floating on the upper layer, which is orange-red to light yellow, and the lower layer is a yellow transparent liquid.

[0069] Example 4 Test of Soluble Solids Content in Astaxanthin-Embedded Microparticle Composition 5.1 Test Method

[0070] Separate the two prisms of the refractometer and clean them with cotton wool dipped in ether or ethanol. Use a glass rod with a fused end to dip 2-3 drops of each composition solution and drop them on the center of the prism surface of the refractometer (Note: 1. When dipping the glass rod into the sample, first remove the upper oily substance of the composition that has stratified, and use the glass rod to remove the lower layer of solution; 2. Do not let the glass rod touch the mirror surface when adding the sample). Quickly close the prism and let it stand for 1 minute to make the test solution uniform and free of bubbles and fill the field of view. Aim at the light source and observe the objective lens through the eyepiece. Adjust the indicator gauge to divide the field of view into light and dark parts, then rotate the fine-tuning screw to make the boundary between light and dark clear, and make the dividing line exactly at the cross point of the objective lens. Read the percentage or refractive index in the field of view of the eyepiece, and record the prism temperature.

[0071] If the eyepiece reading scale is a percentage, it is the soluble solid content (%); if the eyepiece reading scale is a refractive index, it can be converted to the soluble solid content (%) according to Appendix A of GB / T12143. The above percentage content is converted to the soluble solid content (%) at 20°C according to Appendix B of GB / T12143.

[0072] 5.2 Test results

[0073] Table 5 Soluble solids test results

[0074]

[0075]

[0076] The emulsions of compositions 1-26, 33-34, 37-38 were stable, without demulsification and stratification, and the components did not precipitate. The emulsions of compositions 27-32, 35-36, 39-40 stratified, with oily substances precipitated, resulting in a greatly reduced solid content in the emulsion system.

[0077] Example 6 Astaxanthin content test

[0078] 6.1 Experimental methods

[0079] The astaxanthin content was detected by high performance liquid chromatography. The specific detection method is as follows:

[0080] 6.1.1 Chromatographic reference conditions Chromatographic column: YMC Carotenoid, C30, 250×4.6mm, 5μm or a chromatographic column with equivalent performance;

[0081] Mobile phase: A: methanol, B: methyl tert-butyl ether, C: 1% phosphoric acid solution;

[0082] Table 6 Gradient elution

[0083] Time (min) Mobile phase A (%) Mobile phase B (%) Mobile phase C (%) 0 81 15 4 15 66 30 4 23 16 80 4 27 16 80 4 30 81 15 4 35 81 15 4

[0084] Flow rate: 1.0 mL / min; Detection wavelength: 474 nm; Column temperature: 30 °C;

[0085] 6.1.2 Solution preparation

[0086] 6.1.2.1 Preparation of reference solution:

[0087] Accurately weigh about 10 mg of all-trans-astaxanthin reference substance, place it in a 100 mL brown volumetric flask, add 20 mL of chloroform solution to dissolve it, dilute to the scale with acetone solution, shake well, and obtain the reference stock solution (about 100 μg / mL).

[0088] Accurately pipette 2 mL of the control stock solution into a 10 mL brown volumetric flask, dilute to the mark with acetone solution, and shake well to obtain the control intermediate solution (about 20 μg / mL).

[0089] Take an appropriate amount of control intermediate solution, add acetone solution to make a standard series solution of 0.4μg / mL to 10μg / mL, and draw a standard working curve. (The concentration range of the standard curve can be adjusted appropriately according to the sensitivity of the instrument and different instrument models)

[0090] 6.1.2.2 Test solution preparation

[0091] Taking compositions 1-40 as the tested samples, each composition sample was fully shaken, an appropriate amount of each mixed sample was accurately transferred and placed in a 50 mL centrifuge tube, 10 mL of water was added and vortexed for 1 min, then 10 mL of anhydrous ethanol was added and vortexed for 2 min, and the mixture was extracted twice with petroleum ether I, 20 mL each time, and centrifuged at 8000 r / min for 1 min. The two petroleum ether I extracts were collected, evaporated to dryness under reduced pressure at 40°C, and 20 mL of acetone solution was accurately added to dissolve to obtain a sample extract.

[0092] Accurately transfer 3mL of each sample extract to a 15mL centrifuge tube, add 2mL of 0.05mol / L tris(hydroxymethyl)aminomethane solution and shake well, then add 0.3mL of cholesterol esterase solution (10U / mL) and shake well, and place in a 37℃ water bath for enzymatic hydrolysis for 120min (shake well every 30 minutes during this period). Take out, add 0.4g of anhydrous sodium sulfate and 4mL of petroleum ether I to the centrifuge tube, vortex mix for 30s, let stand to allow the solution to separate (if emulsification occurs, centrifuge at 8000r / min for 1min), transfer the petroleum ether layer to a 100mL flat-bottom flask; add 4mL of petroleum ether I to the centrifuge tube, repeat the extraction once, combine the two petroleum ether layer extracts, and evaporate to dryness at 40℃ under reduced pressure. Accurately add 3mL of acetone solution to dissolve, filter through a 0.45μm organic phase filter membrane to obtain the test solution.

[0093] 6.1.3 Detection

[0094] Take the standard curve working solution and the sample solution injection volume: 20μL, inject into the liquid chromatograph, and establish the standard curve equation. The chromatogram of the test sample should show a chromatographic peak with the same retention time as the reference sample chromatographic peak. (Note: Qualitative confirmation is performed by using 9-cis astaxanthin and 13-cis astaxanthin as controls. The relative retention time of cis astaxanthin and all-trans astaxanthin is shown in Table 1. The injection volume can be appropriately adjusted according to the sensitivity of the instrument and different instrument models.)

[0095] Table 7

[0096] Components to be tested Relative retention time ratio with all-trans astaxanthin 13-cis-astaxanthin 0.93 All-trans-astaxanthin 1 9-cis-astaxanthin 1.29

[0097] 6.2 Test results

[0098] 6.2.1 Result calculation

[0099]

[0100] Linear equation: Atrans=aCtrans+b

[0101]

[0102] Xtotal=Xtrans+X9-cis+X13-cis

[0103] Where:

[0104] X—the content of all-trans astaxanthin / 9-cis astaxanthin / 13-cis astaxanthin in the sample, mg / 100g or mg / 100mL;

[0105] XTotal—the content of total astaxanthin in the sample, mg / 100g or mg / 100mL;

[0106] M—mass of sample or sampling volume, g or mL;

[0107] V—dilution volume of the sample, mL;

[0108] C—concentration of all-trans astaxanthin / 9-cis astaxanthin / 13-cis astaxanthin in the sample solution, μg / mL;

[0109] C trans—concentration of all-trans astaxanthin in the sample solution, μg / mL;

[0110] C9-cis—concentration of 9-cis astaxanthin in the sample solution, μg / mL;

[0111] C13-cis—concentration of 13-cis astaxanthin in the sample solution, μg / mL;

[0112] Atrans—peak area of ​​all-trans astaxanthin in the sample;

[0113] A9-cis—peak area of ​​9-cis astaxanthin in the sample;

[0114] A13-cis—peak area of ​​13-cis astaxanthin in the sample;

[0115] a—the slope of the linear equation;

[0116] b—intercept of the linear equation;

[0117] 1.1—9-cis-astaxanthin response factor correction value;

[0118] 1.3—corrected value of response factor for 13-cis-astaxanthin;

[0119] K—unit conversion coefficient (K=0.1);

[0120] 6.2.2 Calculation results

[0121]

[0122] Compositions 1-26, 33-34, 37-38 did not break the emulsion, the oil did not precipitate, the system was not destroyed, and astaxanthin was stably present in the solution system. Combinations 27-32, 35-36, 39-40 had stratification, the solution system was destroyed and stratified, the oil precipitated, and astaxanthin was precipitated, which was degraded by factors such as light, oxygen, and high temperature, and the content decreased.

[0123] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and changes may be made to the details according to all the teachings that have been published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.

Claims

1. A composition comprising astaxanthin-embedded microparticles and glycosaminoglycan; the structure of the astaxanthin-embedded microparticles comprises an inner core and an outer shell; the inner core component comprises astaxanthin, and the outer shell component comprises a skeleton component, a thickener and an emulsifier.

2. The composition according to claim 1, having one or more of the following features: (1) The skeleton components include one or more of resistant dextrin, maltodextrin, and β-cyclodextrin; (2) The thickener includes one or more of gum arabic, xanthan gum, pectin, and guar gum; (3) The emulsifier includes medium chain triglycerides and / or succinic acid glyceride.

3. The composition according to claim 1, characterized in that The composition is uniformly dispersed in water and is in an emulsion state.

4. The composition according to claim 1, characterized in that The mass ratio of the inner core to the outer shell is 1:10-100; preferably, the mass ratio of the inner core to the outer shell is 1:20-50.

5. The composition according to claim 1, characterized in that The mass ratio of the skeleton component, the thickener and the emulsifier is 1-2:2-6:1-2; preferably, the mass ratio of the skeleton component, the thickener and the emulsifier is 1:3:

1.

6. The composition according to claim 1, characterized in that The glycosaminoglycan is selected from one or more of hyaluronic acid, chondroitin sulfate, dermatan sulfate, and keratin sulfate.

7. The composition according to claim 1, characterized in that The composition further comprises collagen; preferably, the collagen is glycosaminoglycan-rich collagen.

8. The composition according to claim 1, characterized in that The mass ratio of the astaxanthin-embedded microparticle microemulsion to glycosaminoglycan is 1:1-10.

9. The method for preparing the composition according to any one of claims 1 to 8, characterized in that: The preparation method comprises the following steps: (1) adding the inner core and outer shell components according to any one of claims 1 to 8 into an appropriate amount of water and stirring until the components are fully dissolved to prepare a solution for use; (2) the solution in step (1) is homogenized by a homogenizer to obtain astaxanthin-embedded microparticles, wherein the astaxanthin-embedded microparticles are uniformly dispersed in water in an emulsion state; (3) Add glycosaminoglycan to the emulsion and stir until fully dissolved, then sterilize in an autoclave to obtain a composition. Preferably, the stirring time in step (1) is 10-40 min, the homogenizing speed in step (2) is 5000-25000 rpm, and the homogenizing speed time is 5-15 min; Preferably, the stirring time in step (3) is 15-30 min; the sterilization temperature in step (3) is 105-121° C., and the sterilization time is 15-30 min.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of medicines, health foods and foods.

Citation Information

Patent Citations

  • Method for preparing astaxanthin microcapsules

    CN104938885A

  • Astaxanthin nano-emulsion with good blending properties, and preparation method for astaxanthin nano-emulsion

    CN111328953A

  • Preparation method of astaxanthin microcapsule

    CN112998270A

  • Natural astaxanthin water-soluble microcapsule and preparation method thereof

    CN114682180A

  • Astaxanthin nanocapsule as well as preparation method and application thereof

    CN114948772A